Short answer · Medically reviewed summary · Last updated: 2026-04-06
Achondroplasia is caused by a specific genetic mutation in the FGFR3 gene, which leads to the overactivity of a protein that inhibits normal bone growth. The Genetic Mechanism The primary cause of Achondroplasia is a gain-of-function mutation in the FGFR3 (fibroblast growth factor receptor 3) gene. Think of the FGFR3 protein as a "brake" on bone growth; in individuals with Achondroplasia, this brake is stuck in the "on" position.
1 people with Achondroplasia have shared their first-person experience on this question at DiseaseMaps.
Which are the causes of Achondroplasia?
Causes of Achondroplasia explained: genetic and environmental factors, reviewed against medical sources, plus patient perspectives.
Achondroplasia is caused by a specific genetic mutation in the FGFR3 gene, which leads to the overactivity of a protein that inhibits normal bone growth.
The Genetic Mechanism
The primary cause of Achondroplasia is a gain-of-function mutation in the FGFR3 (fibroblast growth factor receptor 3) gene. Think of the FGFR3 protein as a "brake" on bone growth; in individuals with Achondroplasia, this brake is stuck in the "on" position. This prevents cartilage from properly converting into bone during development, particularly in the long bones of the arms and legs, resulting in the characteristic short stature associated with the condition.
Inheritance and De Novo Mutations
While Achondroplasia is an autosomal dominant condition, meaning it only requires one copy of the mutated gene to manifest, approximately 80% of cases are not inherited from parents. Instead, they occur as a de novo (spontaneous) mutation during the formation of the sperm or egg. There are no known environmental triggers, dietary factors, or maternal behaviors that cause this mutation. It is purely a biological event, and it is important for families to understand that nothing done during pregnancy causes Achondroplasia.
Current Research and Etiology
The cause of Achondroplasia is fully understood at the molecular level, yet research continues to evolve. Current clinical studies are focused on how we might modulate the overactive FGFR3 pathway to improve bone growth outcomes. Researchers are investigating targeted therapies, such as C-type natriuretic peptide (CNP) analogs, which work to counteract the inhibitory effects of the mutated receptor. By shifting the focus from the cause itself to the downstream signaling pathways, medical science is making significant strides in managing the skeletal complications associated with this condition.
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Achondroplasia
- Orphanet: Achondroplasia (ORPHA:15)
- OMIM (Online Mendelian Inheritance in Man): FGFR3-related skeletal dysplasia
- Little People of America (LPA) Medical Information
Posted Oct 19, 2017 by Kenia Maria 1000
